Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cellsSheng Wang, Maohua Huang, Minfeng Chen, Zhiting Sun, Yubo Jiao, Geni Ye, Jinghua Pan, Wencai Ye, Jianfu Zhao, Dongmei Zhang
9 June 2023
Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitisYanlin Li, Xiaohui Jia, Yajuan Zhang, Yonghao Du, Yuzhu Chang, Yuan Shen, Ziyang Mao, Mengjie Liu, Hong Sun, Hui Guo
8 June 2023
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 studyOmid Hamid, Jessica C Hassel, Alexander N Shoushtari, Friedegund Meier, Todd M Bauer, April K S Salama, John M Kirkwood, Paolo A Ascierto, Paul C Lorigan, Cornelia Mauch, Marlana Orloff, Thomas R Jeffry Evans, Chris Holland, Ramakrishna Edukulla, Shaad E AbedinSee the full list of authors
7 June 2023
Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapyAakash P Desai, Farhad Kosari, Maria Disselhorst, Jun Yin, Alireza Agahi, Tobias Peikert, Julia Udell, Sarah H Johnson, James Smadbeck, Stephen Murphy, Giannoula Karagouga, Alexa McCune, Janet Schaefer-Klein, Mitesh J Borad, John ChevilleSee the full list of authors
6 June 2023
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockadeGiovanni Randon, Yu Aoki, Romain Cohen, Leonardo Provenzano, Vincenzo Nasca, Samuel J Klempner, Steven B Maron, Riccardo Cerantola, Joseph Chao, Lorenzo Fornaro, Walter Ferrari Bravo, Filippo Ghelardi, Margherita Ambrosini, Paolo Manca, Massimiliano SalatiSee the full list of authors
5 June 2023
Optimal dosing regimen of CD73 blockade improves tumor response to radiotherapy through iCOS downregulationLydia Meziani, Marine Gerbé de Thoré, Céline Clémenson, Winchygn Liu, Pierre-Antoine Laurent, Michele Mondini, Marie-Catherine Vozenin, Eric Deutsch
2 June 2023
Management of immune-related cutaneous adverse events with dupilumabAlyce Mei-Shiuan Kuo, Stephanie Gu, Joseph Stoll, Andrea P Moy, Stephen W Dusza, Allison Gordon, Elena C Haliasos, Yelena Janjigian, Lukas Kraehenbuehl, Elizabeth A Quigley, Paul Chapman, Mario E Lacouture, Alina Markova
2 June 2023
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumorsYuxiang Ma, Jinhui Xue, Yuanyuan Zhao, Yang Zhang, Yan Huang, Yunpeng Yang, Wenfeng Fang, Ye Guo, Qun Li, Xiaoxiao Ge, Jie Sun, Bangyong Zhang, Yuhan Zhang, Jinyuan Xiao, Li ZhangSee the full list of authors
1 June 2023
Prognosis of immune checkpoint inhibitors-induced myocarditis: a case seriesCyrille Coustal, Juliette Vanoverschelde, Xavier Quantin, Candice Lesage, Jean-Marie Michot, Ariane Lappara, Stephane Ederhy, Eric Assenat, Maxime Faure, Nahema Issa, Olivier Lambotte, Mathieu Puyade, Olivier Dereure, Diego Tosi, Patricia RullierSee the full list of authors
31 May 2023
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinomaJulius Strauss, Jean-Laurent Deville, Mario Sznol, Alain Ravaud, Marco Maruzzo, Russell K Pachynski, Theodore S Gourdin, Michele Maio, Luc Dirix, Jeffrey Schlom, Renee N Donahue, Yo-Ting Tsai, XiaoZhe Wang, Yulia Vugmeyster, Frank BeierSee the full list of authors
26 May 2023